Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.

@article{Bazerbachi2011ThymoglobulinVB,
  title={Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.},
  author={Fateh Bazerbachi and Markus Selzner and Markus U Boehnert and Max A Marquez and Andrea Norgate and Ian D. McGilvray and Jeffrey R Schiff and Mark S Cattral},
  journal={Transplantation},
  year={2011},
  volume={92 9},
  pages={1039-43}
}
BACKGROUND Thymoglobulin (ATG) and basiliximab induction therapies are used by the majority of centers for pancreas transplantation today. Although both strategies have different mechanisms, there is a paucity of studies comparing them. We compared the efficacy and side effects of both methods in simultaneous pancreas-kidney (SPK) transplantation. METHODS We analyzed 128 SPKs at our institution between January 2001 and August 2008. Forty-nine patients received basiliximab (40 mg), whereas 79… CONTINUE READING